Pulmonx Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Public

  • Employees
  • 296

Employees

  • Stock Symbol
  • LUNG

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $2.74
  • (As of Thursday Closing)

Pulmonx General Information

Description

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Contact Information

Website
www.pulmonx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 700 Chesapeake Drive
  • Redwood City, CA 94063
  • United States
+1 (650)
Primary Industry
Other Devices and Supplies
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 700 Chesapeake Drive
  • Redwood City, CA 94063
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pulmonx Stock Performance

As of 19-Nov-2026, Pulmonx’s stock price is $2.74. Its current market cap is $119M with 43.6M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.74 $2.69 $1.13 - $3.25 $119M 43.6M 637K -$1.01

Pulmonx Financials Summary

As of 30-Sep-2026, Pulmonx has a trailing 12-month revenue of $88.8M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 82,399 71,171 216,153 414,164
Revenue 88,775 90,497 83,789 68,675
EBITDA (38,325) (51,819) (55,955) (61,060)
Net Income (42,553) (54,003) (56,394) (60,843)
Total Assets 110,212 129,291 162,850 177,781
Total Debt 56,346 56,364 56,471 41,424
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pulmonx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pulmonx‘s full profile, request access.

Request a free trial

Pulmonx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Pulmonx‘s full profile, request access.

Request a free trial

Pulmonx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients
Other Devices and Supplies
Redwood City, CA
296 As of 2025

San Jose, CA
 

Audubon, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pulmonx Competitors (5)

One of Pulmonx’s 5 competitors is Broncus Medical, a Formerly VC-backed company based in San Jose, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Broncus Medical Formerly VC-backed San Jose, CA
Globus Medical Formerly VC-backed Audubon, PA
Sanovas Formerly VC-backed Petaluma, CA
Hill-Rom Corporation Essen, Germany
ELITechGroup Formerly PE-Backed Puteaux, France
You’re viewing 5 of 5 competitors. Get the full list »

Pulmonx Patents

Pulmonx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021322211-A1 Methods, systems, and devices for analyzing lung imaging data to determine collateral ventilation Active 06-Aug-2020
AU-2021322211-B2 Methods, systems, and devices for analyzing lung imaging data to determine collateral ventilation Active 06-Aug-2020
AU-2026257567-A1 Methods, systems, and devices for analyzing lung imaging data to determine collateral ventilation Pending 06-Aug-2020
EP-4192346-A1 Methods, systems, and devices for analyzing lung imaging data to determine collateral ventilation Pending 06-Aug-2020
EP-4192346-A4 Methods, systems, and devices for analyzing lung imaging data to determine collateral ventilation Pending 06-Aug-2020 G06T7/0012
To view Pulmonx’s complete patent history, request access »

Pulmonx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pulmonx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pulmonx‘s full profile, request access.

Request a free trial

Pulmonx Acquisitions (2)

Pulmonx’s most recent deal was a Merger/Acquisition with Aeris Therapeutics. The deal was made on 08-Jan-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aeris Therapeutics 08-Jan-2015 Merger/Acquisition Therapeutic Devices
Emphasys Medical 13-May-2009 Merger/Acquisition Other Devices and Supplies
To view Pulmonx’s complete acquisitions history, request access »

Pulmonx ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.53 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Devices

Subindustry

of 209

Rank

Percentile

To view Pulmonx’s complete esg history, request access »

Pulmonx FAQs

  • When was Pulmonx founded?

    Pulmonx was founded in 1995.

  • Where is Pulmonx headquartered?

    Pulmonx is headquartered in Redwood City, CA.

  • What is the size of Pulmonx?

    Pulmonx has 296 total employees.

  • What industry is Pulmonx in?

    Pulmonx’s primary industry is Other Devices and Supplies.

  • Is Pulmonx a private or public company?

    Pulmonx is a Public company.

  • What is Pulmonx’s stock symbol?

    The ticker symbol for Pulmonx is LUNG.

  • What is the current stock price of Pulmonx?

    As of 19-Nov-2026 the stock price of Pulmonx is $2.74.

  • What is the current market cap of Pulmonx?

    The current market capitalization of Pulmonx is $119M.

  • What is Pulmonx’s current revenue?

    The trailing twelve month revenue for Pulmonx is $88.8M.

  • Who are Pulmonx’s competitors?

    Broncus Medical, Globus Medical, Sanovas, Hill-Rom, and ELITechGroup are competitors of Pulmonx.

  • What is Pulmonx’s annual earnings per share (EPS)?

    Pulmonx’s EPS for 12 months was -$1.01.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process